AIMS: Continuous infusion of prostacyclin analogues improves survival in advanced pulmonary arterial hypertension. In addition to its vasodilatory effects, prostacyclin has the potential to decrease inflammation, thrombosis, and smooth muscle proliferation. The aim of this retrospective study was to determine whether pathological data support the ability of prostanoids to prevent progression of vascular disease. METHODS AND RESULTS: Twenty-two autopsied patients with World Health Organization category 1 pulmonary arterial hypertension (primarily idiopathic and connective tissue disease-associated) were divided into those who received long-term prostacyclin (n = 12, PG-long, mean treatment 3.9 years) and those who received 0-1 month of prostacyclin (n = 10, PG-short). Surprisingly, PG-long patients had larger plexiform lesions (P < 0.05), with no decrease in medial and intimal thicknesses as compared with PG-short patients. Plexiform lesion size and density increased with increasing treatment time. Also, PG-long patients had fewer platelet thrombi and more frequent acute diffuse alveolar haemorrhage. Quantification of macrophages and T cells revealed no differences in inflammatory infiltrates. CONCLUSION: Although long-term prostacyclin therapy may have an antithrombotic effect in addition to its vasodilatory actions, it was not associated with the prevention of advanced vascular lesions. The mechanism by which prostacyclin analogues improve survival in pulmonary arterial hypertension remains uncertain.
AIMS: Continuous infusion of prostacyclin analogues improves survival in advanced pulmonary arterial hypertension. In addition to its vasodilatory effects, prostacyclin has the potential to decrease inflammation, thrombosis, and smooth muscle proliferation. The aim of this retrospective study was to determine whether pathological data support the ability of prostanoids to prevent progression of vascular disease. METHODS AND RESULTS: Twenty-two autopsied patients with World Health Organization category 1 pulmonary arterial hypertension (primarily idiopathic and connective tissue disease-associated) were divided into those who received long-term prostacyclin (n = 12, PG-long, mean treatment 3.9 years) and those who received 0-1 month of prostacyclin (n = 10, PG-short). Surprisingly, PG-longpatients had larger plexiform lesions (P < 0.05), with no decrease in medial and intimal thicknesses as compared with PG-shortpatients. Plexiform lesion size and density increased with increasing treatment time. Also, PG-longpatients had fewer platelet thrombi and more frequent acute diffuse alveolar haemorrhage. Quantification of macrophages and T cells revealed no differences in inflammatory infiltrates. CONCLUSION: Although long-term prostacyclin therapy may have an antithrombotic effect in addition to its vasodilatory actions, it was not associated with the prevention of advanced vascular lesions. The mechanism by which prostacyclin analogues improve survival in pulmonary arterial hypertension remains uncertain.
Authors: Rosane O D Achcar; Gordon L Yung; Helene Saffer; Carlyne D Cool; Norbert F Voelkel; Eunhee S Yi Journal: Eur J Med Res Date: 2006-05-05 Impact factor: 2.175
Authors: T Murata; F Ushikubi; T Matsuoka; M Hirata; A Yamasaki; Y Sugimoto; A Ichikawa; Y Aze; T Tanaka; N Yoshida; A Ueno; S Oh-ishi; S Narumiya Journal: Nature Date: 1997-08-14 Impact factor: 49.962
Authors: R J Barst; L J Rubin; W A Long; M D McGoon; S Rich; D B Badesch; B M Groves; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; L M Clayton; M M Jöbsis; S D Blackburn; D Shortino; J W Crow Journal: N Engl J Med Date: 1996-02-01 Impact factor: 91.245
Authors: G Montalescot; G Drobinski; P Meurin; J Maclouf; I Sotirov; F Philippe; R Choussat; E Morin; D Thomas Journal: Am J Cardiol Date: 1998-09-15 Impact factor: 2.778
Authors: Laura A Adang; David B Frank; Ahmed Gilani; Asako Takanohashi; Nicole Ulrick; Abigail Collins; Zachary Cross; Csaba Galambos; Guy Helman; Usama Kanaan; Stephanie Keller; Dawn Simon; Omar Sherbini; Brian D Hanna; Adeline L Vanderver Journal: Mol Genet Metab Date: 2018-09-07 Impact factor: 4.797
Authors: Ketul R Chaudhary; Yupu Deng; Colin M Suen; Mohamad Taha; Thomas H Petersen; Shirley H J Mei; Duncan J Stewart Journal: Br J Pharmacol Date: 2018-09-16 Impact factor: 8.739
Authors: Shinji Toki; Kasia Goleniewska; Matthew M Huckabee; Weisong Zhou; Dawn C Newcomb; Garret A Fitzgerald; William E Lawson; R Stokes Peebles Journal: J Leukoc Biol Date: 2013-04-26 Impact factor: 4.962
Authors: Salina Gairhe; Sachindra R Joshi; Mrigendra M Bastola; Jared M McLendon; Masahiko Oka; Karen A Fagan; Ivan F McMurtry Journal: Pulm Circ Date: 2016-09 Impact factor: 3.017
Authors: Ji Young Lee; C Michael Francis; Natalie N Bauer; Natalie R Gassman; Troy Stevens Journal: Am J Physiol Lung Cell Mol Physiol Date: 2020-03-19 Impact factor: 6.011